What is B. Riley’s Estimate for CRBP Q1 Earnings?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Investment analysts at B. Riley issued their Q1 2025 earnings per share estimates for shares of Corbus Pharmaceuticals in a note issued to investors on Thursday, March 13th. B. Riley analyst K. Patel anticipates that the biopharmaceutical company will post earnings of ($0.92) per share for the quarter. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.23) per share. B. Riley also issued estimates for Corbus Pharmaceuticals’ Q2 2025 earnings at ($0.92) EPS and Q3 2025 earnings at ($0.92) EPS.

A number of other brokerages have also recently commented on CRBP. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target (down previously from $75.00) on shares of Corbus Pharmaceuticals in a research report on Wednesday. William Blair started coverage on Corbus Pharmaceuticals in a report on Friday, February 28th. They issued an “outperform” rating for the company. Wedbush reissued an “outperform” rating and issued a $51.00 price objective on shares of Corbus Pharmaceuticals in a report on Wednesday. Piper Sandler initiated coverage on Corbus Pharmaceuticals in a report on Monday, December 2nd. They issued an “overweight” rating and a $35.00 price objective for the company. Finally, StockNews.com raised Corbus Pharmaceuticals to a “sell” rating in a report on Thursday, March 6th. One investment analyst has rated the stock with a sell rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Corbus Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $59.13.

Corbus Pharmaceuticals Stock Performance

Shares of CRBP opened at $6.79 on Friday. The stock has a 50-day moving average of $9.44 and a two-hundred day moving average of $18.72. Corbus Pharmaceuticals has a one year low of $6.38 and a one year high of $61.90. The stock has a market cap of $82.70 million, a P/E ratio of -1.45 and a beta of 2.63.

Corbus Pharmaceuticals (NASDAQ:CRBP) last issued its quarterly earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.78) EPS for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.24.

Institutional Investors Weigh In On Corbus Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Vestcor Inc purchased a new stake in shares of Corbus Pharmaceuticals in the third quarter valued at approximately $64,000. Wells Fargo & Company MN grew its position in shares of Corbus Pharmaceuticals by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 6,444 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 2,195 shares in the last quarter. Avanza Fonder AB purchased a new stake in shares of Corbus Pharmaceuticals in the fourth quarter valued at approximately $84,000. Deutsche Bank AG grew its position in shares of Corbus Pharmaceuticals by 46.8% in the fourth quarter. Deutsche Bank AG now owns 8,206 shares of the biopharmaceutical company’s stock valued at $97,000 after purchasing an additional 2,616 shares in the last quarter. Finally, Aquatic Capital Management LLC purchased a new stake in shares of Corbus Pharmaceuticals in the fourth quarter valued at approximately $101,000. 64.64% of the stock is currently owned by hedge funds and other institutional investors.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.